HuaminHenryLiMDPhD, CPI

Allergy & Immunology • Chevy Chase, MD

Asthma & Allergic Conditions

Institute for Asthma and Allergy

Join to view full profile

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Li's full profile

Already have an account?

Office
2 Wisconsin Cir
Suite 250
Chevy Chase, MD 20815
Phone+1 301-986-9262

Fax+1 301-907-7910

Education & Training

Johns Hopkins UniversityFellowship, Allergy and Immunology, 2001
Rutgers Health/Cooperman Barnabas Medical CenterResidency, Internal Medicine, 1999
Rutgers Health/Cooperman Barnabas Medical CenterInternship, Internal Medicine, 1996 - 1997
University of Texas Medical BranchPhD, 1992 - 1996
University of Texas Medical BranchPhD, 1992 - 1996
Tianjin Medical UniversityClass of 1988

Certifications & Licensure

NJ State Medical License Current
FL State Medical License 2024 - 2026
MD State Medical License 1999 - 2026
NY State Medical License 2023 - 2025
DC State Medical License 2002 - 2024
VA State Medical License 2023 - 2024
American Board of Allergy and Immunology Allergy & Immunology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants Start of enrollment: 2014 May 14
Completed
Phase 1
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Start of enrollment: 2021 Feb 05
Completed
Phase 3
Roles: Principal Investigator

Publications & Presentations

PubMed

12 citations
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossov...
Emel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, Mauro Cancian, Roman Hakl
Lancet. 2023-02-11
Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies.
Timothy J Craig, Rafael H Zaragoza-Urdaz, H Henry Li, Ming Yu, Hong Ren
Allergy, Asthma, and Clinical Immunology. 2022-09-24
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioed...
William R Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson
Orphanet Journal of Rare Diseases. 2021-07-28

Journal Articles

Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema Attacks
Jonathan A Bernstein, Lawrence B Schwartz, Andrew M Smith, H James Wedner, Daniel Soteres, Timothy Craig, Douglas T Johnston, Aleena Banerji, Paula J Busse, William R ..., JAMA
Population Pharmacokinetics of Subcutaneous C1‐Inhibitor for Prevention of Attacks in Patients with Hereditary Angioedema
Jonathan A Bernstein, Marc A Riedl, Bruce Zuraw, H Henry Li, Timothy Craig, William R Lumry, Clinical and experimental allergy

Professional Memberships

American Academy of Allergy Asthma and Immunology - AAAAI
Fellow

Other Languages

Chinese (Mandarin)